26 April 2023
Latham Advises CHEPLAPHARM on Acquisition of Zyprexa® and Bridge Loan
Advising firms
Deal team
12 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Christoph Engeler Lead | Latham & Watkins LLP | Partner | Healthcare & Life Sciences | Not stated |
| Alexandra Hagelüken | Latham & Watkins LLP | Partner | finance | Not stated |
| Henrietta Ditzen | Latham & Watkins LLP | Associate | Not stated | Düsseldorf |
| Katarina Fröschle | Latham & Watkins LLP | Associate | Not stated | Hamburg |
| Edward Martin | Latham & Watkins LLP | Associate | Not stated | Hamburg |
| Cora Grannemann | Latham & Watkins LLP | Counsel | Not stated | Frankfurt |
| Anastasia Dressler | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Kate Zhu | Latham & Watkins LLP | Associate | Not stated | Not stated |
| Susan Kempe-Müller | Latham & Watkins LLP | Partner | IP | Frankfurt |
| Daniela Jaeger | Latham & Watkins LLP | Associate | IP | Not stated |
| Wolf-Tassilo Böhm | Latham & Watkins LLP | Counsel | data privacy | Frankfurt |
| Tobias Klass | Latham & Watkins LLP | Partner | tax | Hamburg |
Stated terms
- Stated value
- EUR 750m (€750 million)
- What the figure measures
- Facility amount
- Client
- CHEPLAPHARM Arzneimittel GmbHBuy-side
- Counterparties
- Eli Lilly and Company (Sell-side)